Publications | Marques Lab

2026

Front. Microbiol. New · Open Access

Leishmaniasis: pathogenesis, host immunity, and the evolving landscape of immunotherapy and immunochemotherapy

Okeke GN, Oduwe UK, Kenkebashvili G, Tabassum S, Marques AF*. Frontiers in Microbiology. 2026;17:1861933.

doi:10.3389/fmicb.2026.1861933 ↗

2025

Lancet Microbe

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: a secondary analysis of individual patient data from two proof-of-concept trials

Watson JA, Cruz C, Barreira F, et al., Marques AF, on behalf of the E1224 and BENDITA Study Group. Lancet Microbe. 2025;6(10):101156.

doi:10.1016/j.lanmic.2025.101156 ↗

2025

PLoS Negl Trop Dis

K-mer-based approach for serodiagnostic antigen discovery in Chagas disease using unassembled sequencing reads

et al., Marques AF. PLoS Negl Trop Dis. 2025.

doi:10.1371/journal.pntd.0013835 ↗

2025

Front Cell Infect Microbiol

Differential antioxidant enzyme profiles reveal early molecular signatures of virulence in Trypanosoma cruzi

et al., Marques AF. Front Cell Infect Microbiol. 2025.

doi:10.3389/fcimb.2025.1664827 ↗

2024

Parasitology

Understanding American tegumentary leishmaniasis in urban Montes Claros, Brazil: insights from clinical, immunological and therapeutic investigations

Lopes DMS, Lima JMS, Ribeiro KSM, et al., Finn MG, Venuto AP, Marques AF. Parasitology. 2024;151(11):1260–1268.

doi:10.1017/S0031182024001057 ↗

2022

Curr Trop Med Rep

Possibility of Leishmania Transmission via Lutzomyia spp. Sand Flies Within the USA

Beasley et al. Curr Trop Med Rep. 2022;9(4):160–168.

2021

PLoS Negl Trop Dis

α-Gal immunization positively impacts Trypanosoma cruzi colonization of heart tissue in a mouse model

Rodrigues da Cunha GM, Azevedo MA, Nogueira DS, et al., Marques AF. PLoS Negl Trop Dis. 2021;15(7):e0009613.

doi:10.1371/journal.pntd.0009613 ↗

2020

ACS Infect Dis

C57BL/6 α-1,3-Galactosyltransferase Knockout Mouse as an Animal Model for Experimental Chagas Disease

Ayala EV, Rodrigues da Cunha G, et al., Marques AF. ACS Infect Dis. 2020;6(7):1807–1815.

doi:10.1021/acsinfecdis.0c00061 ↗

2019

npj Vaccines

A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease

Portillo S, Zepeda BG, Iniguez E, et al., Marques AF. npj Vaccines. 2019;4(1):13. (85 citations)

doi:10.1038/s41541-019-0109-3 ↗

2017

ACS Cent Sci

Virus-like Particle Display of the α-Gal Carbohydrate for Vaccination against Leishmania Infection

Moura APV, Santos LCB, Brito CRN, et al., Marques AF*. ACS Cent Sci. 2017;3(9):1026–1031. (86 citations)

doi:10.1021/acscentsci.7b00311 ↗

2016

ACS Infect Dis

Virus-like Particle Display of the α-Gal Epitope for the Diagnostic Assessment of Chagas Disease

Brito CRN, McKay CS, Azevedo MA, et al., Marques AF. ACS Infect Dis. 2016;2:917–922.

2016

Int J Parasitol

Amblyomma sculptum tick saliva: α-Gal identification, antibody response and possible association with red meat allergy in Brazil

Araujo RN, Franco PF, et al., Marques AF. Int J Parasitol. 2016;46(3):213–220. (151 citations)

doi:10.1016/j.ijpara.2015.12.005 ↗

2014

Vaccine

A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease

Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, et al. Vaccine. 2014;32(28):3525–3532. (85 citations)